Weight Loss Industry Poised for Revolution With GLP-1 Pills

  • Flu cases are on the rise in the US, with activity very high in the Northeast

    03:01

  • Currently playing

    Weight-loss drug giants are preparing to debut oral GLP-1 variants

    03:29

  • NEXT

    Health insurance premiums for millions of Americans will rise sharply

    02:03

  • Officials warn of surge in flu cases amid holiday season

    02:12

  • Flu cases surge in record numbers in US

    00:18

  • Try these tips to stay healthy during the holiday season.

    04:28

  • Barry Manilow announces lung cancer diagnosis, but postpones appearances

    02:51

  • FDA Approves Tablet Version of Wegovy: What You Need to Know

    03:23

  • Flu cases rise across the country as families flock for the holidays

    02:23

  • Feeling overwhelmed by the holidays? How to manage stress

    05:43

  • How to protect yourself from a surge in flu and whooping cough cases

    03:56

  • James Van Der Beek talks to TODAY about his battle with cancer

    06:42

  • House Passes GOP Health Care Bill Without Extending Subsidies

    02:17

  • Flu cases surge in US as holidays approach

    04:13

  • How to protect yourself as cold and flu season ramps up

    03:44

  • The FDA has issued a warning to retailers selling the recalled baby food.

    00:33

  • How to rethink the way we talk and think about menopause

    05:17

  • Can lawmakers find a solution to expiring health care subsidies?

    05:04

  • Is the K-Beauty trend really worth all the hype?

    04:37

  • New Eli Lilly Weight Loss Drug Burns Fat and Reduces Knee Pain

    01:12

As Americans focus on getting in shape in the new year, a groundbreaking new option is expected to change the weight-loss landscape as two pharmaceutical giants prepare to debut their oral GLP-1 variants. Last week, the FDA approved Novo Nordisk's once-daily Wegovy pill, and Eli Lilly is awaiting FDA approval for its pill that has helped adults lose 27 pounds in 72 weeks. NBC's Maggie Vespa reports for TODAY.

Leave a Comment